Compare Abercrombie & Fitch Co. (ANF) vs Canopy Growth Corp (CGC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abercrombie & Fitch Co. vs Canopy Growth Corp — how do they compare? Abercrombie & Fitch Co. trades at $91.98 (market cap $4.14B), while Canopy Growth Corp trades at $0.97 (market cap $407.38M). The key difference: Abercrombie & Fitch Co. is far larger — about 10.2× Canopy Growth Corp's market cap, and Abercrombie & Fitch Co. is trading nearer its 52-week high, Canopy Growth Corp nearer its low. Which is the better fit depends on your goals.
| ANF | CGC | |
|---|---|---|
Market Cap | $4.14B | $407.38M |
Sector | Consumer Cyclical | Health |
52-Week High | $129.85 | $1.92 |
52-Week Low | $65.61 | $0.86 |
Enterprise Value | $4.81B | $346.82M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abercrombie & Fitch (ANF) trades at $93.07, up 4.29% with strong fundamental metrics including a P/E of 9 and net income margin of 9.34%. The stock shows consistent earnings beats in recent quarters and maintains robust profitability with ROE at 39.04%. Technical indicators are neutral overall, with bullish moving averages and key resistance at $94. Recent expansion initiatives include APAC growth opportunities and partnerships with Target for back-to-college merchandise.
ANF presents a compelling value opportunity with attractive valuation multiples and strong operational performance. Upside potential exists to the $107.71 consensus price target, though risks include moderating sales growth and international market volatility. The company's disciplined expansion and brand revitalization support long-term growth prospects.
Canopy Growth (CGC) trades at $0.97, down 0.28% on the day, with a mixed technical picture showing a bullish overall signal but bearish moving averages. The company reported a net loss of $598.12 million in 2025, with revenue declining to $269 million, though recent quarterly earnings showed one beat and two misses. Cash flow remains negative, but the balance sheet improved with a debt-to-asset ratio of 33.13% in 2025. Analyst sentiment is divided, with 33% buy ratings amid ongoing profitability challenges and potential reverse stock split discussions.
The outlook for CGC hinges on achieving profitability and navigating regulatory hurdles, with projected revenue growth to $285 million in 2026 offering a potential catalyst. Key risks include persistent losses, high debt, and Nasdaq compliance concerns, while institutional interest remains cautious. Investors should weigh the speculative turnaround potential against significant financial and operational headwinds in the volatile cannabis sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abercrombie & Fitch Co.
Abercrombie & Fitch Co is a specialty retailer that sells casual clothing, personal-care products, and accessories for men, women, and children. It sells direct to consumer through its stores and websites, which include the Abercrombie & Fitch, Abercrombie kids, and Hollister brands. Most stores are in the United States, but the company does have many stores in Canada, Europe, and Asia. All stores are leased. Abercrombie ships to well over 100 countries via its websites. The company sources its merchandise from dozens of vendors that are primarily located in Asia and Central America. Abercrombie has two distribution centers in Ohio to support its North American operations. It uses third-party distributors for sales in Europe and Asia.
Read more on ANF →About Canopy Growth Corp
Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Tweed, Spectrum Therapeutics, and CraftGrow. Although it primarily operates in Canada, Canopy has distribution and production licenses in more than a dozen countries to drive expansion in global medical cannabis and also holds an option to acquire Acreage Holdings upon U.S. federal cannabis legalization.
Read more on CGC →
